Apyx Medical Q2 revenue beats estimates on surgical aesthetics growth

Apyx Medical

06/08/2026 21:40

Overview
Surgical aesthetics firm's Q2 revenue rose 22% yr/yr, beating analyst expectations
Q2 adjusted EBITDA loss narrowed and beat analyst expectations
Company reaffirmed FY2026 revenue guidance of $59 mln to $60 mln

Outlook
Apyx Medical reaffirms 2026 revenue guidance of $59.0 mln to $60.0 mln
Company expects 2026 Surgical Aesthetics revenue of $54.0 mln to $55.0 mln
OEM revenue for 2026 expected to be about $5.0 mln, down from $7.5 mln in 2025

Result Drivers
SURGICAL AESTHETICS GROWTH - Revenue growth driven by increased sales of AYON, Renuvion generators internationally, and single-use handpieces domestically
SEGMENT MIX - Higher percentage of Surgical Aesthetics sales contributed to improved gross margin
OEM REVENUE DECLINE - OEM segment revenue fell due to lower sales volume to existing customers

Company press release: ID:nGNX7kFqtg

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$13.88 mln
$13.18 mln (5 Analysts)
Q2 Loss Per Share
 
$0.07
 
Q2 Net Loss
 
$3.07 mln
 
Q2 Adjusted EBITDA
Beat
-$705,000
-$1.86 mln (3 Analysts)
Q2 Gross Margin
 
63.90%
 
Q2 Income From Operations
 
-$1.81 mln
 
Q2 Pretax Loss
 
$2.95 mln
 

Reuters Recommended Reads
Aug 5 - InMode Q2 revenue beats estimates on steady U.S. demand
Aug 5 - Evolus Q2 revenue rises 21%, lifts 2026 outlook
Aug 6 - Establishment Labs Q2 revenue rises, beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)